Abeona Therapeutics Future Growth
Future criteria checks 2/6
Abeona Therapeutics is forecast to grow earnings and revenue by 53.6% and 54% per annum respectively while EPS is expected to grow by 58.5% per annum.
Key information
53.6%
Earnings growth rate
58.5%
EPS growth rate
Biotechs earnings growth | 31.3% |
Revenue growth rate | 54.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 89 | -26 | 13 | N/A | 4 |
12/31/2025 | 23 | -64 | -46 | N/A | 4 |
12/31/2024 | 1 | -60 | N/A | N/A | 4 |
12/31/2023 | 4 | -54 | -37 | -37 | N/A |
9/30/2023 | 4 | -45 | -42 | -42 | N/A |
6/30/2023 | 4 | -39 | -43 | -43 | N/A |
3/31/2023 | 1 | -31 | -42 | -42 | N/A |
12/31/2022 | 1 | -43 | -44 | -43 | N/A |
9/30/2022 | 4 | -83 | -63 | -60 | N/A |
6/30/2022 | 4 | -84 | -67 | -63 | N/A |
3/31/2022 | 3 | -91 | -70 | -66 | N/A |
12/31/2021 | 3 | -85 | -70 | -66 | N/A |
9/30/2021 | 3 | -54 | -38 | -37 | N/A |
6/30/2021 | 10 | -54 | -38 | -37 | N/A |
3/31/2021 | 10 | -52 | -37 | -35 | N/A |
12/31/2020 | 10 | -84 | -36 | -35 | N/A |
9/30/2020 | 7 | -85 | -49 | -48 | N/A |
6/30/2020 | N/A | -95 | -57 | -55 | N/A |
3/31/2020 | N/A | -106 | -67 | -61 | N/A |
12/31/2019 | N/A | -76 | -69 | -63 | N/A |
9/30/2019 | 0 | -77 | -83 | -66 | N/A |
6/30/2019 | 2 | -76 | -74 | -56 | N/A |
3/31/2019 | 2 | -65 | -67 | -50 | N/A |
12/31/2018 | 3 | -57 | -59 | -39 | N/A |
9/30/2018 | 3 | -48 | -36 | -27 | N/A |
6/30/2018 | 1 | -37 | -33 | -25 | N/A |
3/31/2018 | 1 | -33 | -25 | -21 | N/A |
12/31/2017 | 1 | -27 | -24 | -23 | N/A |
9/30/2017 | 1 | -26 | N/A | -21 | N/A |
6/30/2017 | 1 | -23 | N/A | -18 | N/A |
3/31/2017 | 1 | -22 | N/A | -16 | N/A |
12/31/2016 | 1 | -22 | N/A | -13 | N/A |
9/30/2016 | 1 | -17 | N/A | -12 | N/A |
6/30/2016 | 1 | -21 | N/A | -11 | N/A |
3/31/2016 | 1 | -18 | N/A | -10 | N/A |
12/31/2015 | 1 | -15 | N/A | -10 | N/A |
9/30/2015 | 1 | -25 | N/A | -9 | N/A |
6/30/2015 | 1 | -21 | N/A | -6 | N/A |
3/31/2015 | 1 | -30 | N/A | -5 | N/A |
12/31/2014 | 1 | -30 | N/A | -2 | N/A |
9/30/2014 | 1 | -19 | N/A | -1 | N/A |
6/30/2014 | 1 | -17 | N/A | -2 | N/A |
3/31/2014 | 1 | -3 | N/A | 0 | N/A |
12/31/2013 | 2 | 2 | N/A | 0 | N/A |
9/30/2013 | 3 | 22 | N/A | -1 | N/A |
6/30/2013 | 4 | 8 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PCJ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PCJ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PCJ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PCJ's revenue (54% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: PCJ's revenue (54% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PCJ's Return on Equity is forecast to be high in 3 years time